Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

18 Jul 2013

Abstract excerpt

BACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) are anticancer agents targeting epigenetic regulation of gene expression and are in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23868005
DOI: 10.1038/bjc.2013.392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitorsPMID 23868005Read ↗

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsSemantic proximity Read ↗

The biological significance of histone modifiers in multiple myeloma: clinical applicationsSemantic proximity Read ↗

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma TherapySemantic proximity Read ↗

Chemogenomics Mapping of Potential Drugs and Targets for Treatment of Multiple MyelomaSemantic proximity Read ↗

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetSemantic proximity Read ↗

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Role of epigenetics-microRNA axis in drug resistance of multiple myelomaSemantic proximity Read ↗

SUMOylation Inhibition Enhances Dexamethasone Sensitivity in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.